Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $41,534 | $34,030 | $21,627 | $33,572 |
| % Growth | 22.1% | 57.3% | -35.6% | – |
| Cost of Goods Sold | $27,898 | $13,168 | $12,410 | $13,052 |
| Gross Profit | $13,636 | $20,862 | $9,217 | $20,520 |
| % Margin | 32.8% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | $10,612 | $7,647 | $11,514 | $11,386 |
| G&A Expenses | $8,721 | $10,365 | $11,652 | $11,138 |
| SG&A Expenses | $18,616 | $19,672 | $21,021 | $21,360 |
| Sales & Mktg Exp. | $9,895 | $9,307 | $9,369 | $10,222 |
| Other Operating Expenses | $16,301 | $2,155 | $53 | -$340 |
| Operating Expenses | $45,529 | $29,474 | $32,588 | $32,406 |
| Operating Income | -$19,550 | -$8,612 | -$23,371 | -$11,886 |
| % Margin | -47.1% | -25.3% | -108.1% | -35.4% |
| Other Income/Exp. Net | -$8,288 | -$2,750 | -$879 | -$3,030 |
| Pre-Tax Income | -$27,838 | -$11,362 | -$24,250 | -$14,916 |
| Tax Expense | $655 | $277 | $315 | $735 |
| Net Income | -$39,876 | -$11,085 | -$24,565 | -$15,651 |
| % Margin | -96% | -32.6% | -113.6% | -46.6% |
| EPS | -0.008 | -0.002 | -0.005 | -0.006 |
| % Growth | -265.2% | 55.8% | 10.3% | – |
| EPS Diluted | -0.008 | -0.002 | -0.005 | -0.006 |
| Weighted Avg Shares Out | 4,766,440 | 4,767,742 | 4,767,126 | 2,720,224 |
| Weighted Avg Shares Out Dil | 4,766,440 | 4,766,440 | 4,766,440 | 2,720,224 |
| Supplemental Information | – | – | – | – |
| Interest Income | $232 | $0 | -$33 | $318 |
| Interest Expense | $5,770 | $2,750 | $0 | $6,378 |
| Depreciation & Amortization | $3,792 | $1,935 | $55 | $2,114 |
| EBITDA | -$36,249 | -$4,151 | -$22,814 | -$9,352 |
| % Margin | -87.3% | -12.2% | -105.5% | -27.9% |